| Literature DB >> 32416901 |
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32416901 PMCID: PMC7220170 DOI: 10.1016/j.tjog.2020.03.025
Source DB: PubMed Journal: Taiwan J Obstet Gynecol ISSN: 1028-4559 Impact factor: 1.705
SARS infection and maternal–fetal outcome.
| Country | Case | Maternal | Newborn | |||
|---|---|---|---|---|---|---|
| Complication | SARS-CoV Antibody | Delivery | Complication | SARS-CoV antibody | ||
| United States | 1 | Progressive Lung Infiltration s/p Mechanical Ventilation | Serum (+) | 38 weeks | No adverse effect | Cord blood (+) |
| 2 | Lung infiltration s/p antibiotics | Serum (+) | 36 weeks Cesarean | No adverse effect | Cord blood (−) | |
| Hong Kong | 1 | SARS fatality with MRSA pneumonia | Nasopharyngeal (+) | 28 weeks | Necrotizing Enterocolitis with ileal perforation s/p laparotomy | Cord blood (−) |
| 2 | Lung infiltration s/p antibiotics | Stool (+) | 26 weeks | Jejunal perforation s/p laparotomy | Cord blood (−) | |
| 3 | SARS fatality | Stool (+) | 32 weeks | No adverse effect | Cord blood (−) | |
| 4 | Lung infiltration s/p antibiotics | Nasopharyngeal (+) | 33 weeks | No adverse effect | Cord blood (−) | |
| 5 | Progressive Lung Infiltration s/p Mechanical Ventilation | Stool (+) | 37 weeks | No adverse effect | Cord blood (−) | |
| Others | 4 miscarriage | |||||
MERS infection and maternal–fetal outcome.
| Country | Cases | Maternal | Newborn | |||
|---|---|---|---|---|---|---|
| Complication | MERS-CoV antibody | Delivery | Complication | MERS-CoV antibody | ||
| Saudi Arabia | 1 | Asymptomatic | Nasopharyngeal (+) | Term | No Adverse Effects | X |
| 2 | Asymptomatic | Nasopharyngeal (+) | Term | No Adverse Effects | X | |
| 3 | Lung infiltration s/p antibiotics | Nasopharyngeal (+) | 34 weeks | IUFD | X | |
| 4 | MERS Fatality | Nasopharyngeal (+) | 38 weeks | No Adverse Effects | X | |
| 5 | MERS Fatality | Nasopharyngeal (+) | 24 weeks | Preterm Expire | X | |
| 6 | Lung infiltration s/p antibiotics | Nasopharyngeal (+) | Term | No Adverse Effect | X | |
| 7 | Progressive Lung Infiltration s/p Mechanical Ventilation | Nasopharyngeal (+) | Term | No Adverse Effect | X | |
| 8 | Progressive Lung Infiltration s/p Mechanical Ventilation | Nasopharyngeal (+) | 32 weeks | No Adverse Effect | X | |
| Jordan | 1 | Refuse treatment | EIA (+) | 20 weeks | IUFD | X |
| United Arab | 1 | MERS Fatality | Nasopharyngeal (−) | 32 weeks | No Adverse Effects | X |
| South Korea | 1 | Lung infiltration s/p antibiotics | RT-PCR (+) | 37 + 5 weeks | No Adverse Effects | Cord blood (−) |